16 completed, 3 recruiting, 2 unknown, 1 terminated. 23 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 23 | Completed 16, Recruiting 3, Unknown 2, Terminated 1, Withdrawn 1 |
| Phase 2 | 5 | Completed 4, Unknown 1 |
Follow Esketamine: new trials by email Literature Review of Esketamine trials Research Report on Esketamine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression Esketamine 56 mg, Esketamine 84 mg, Placebo - Depressive Disorder, Treatment-Resistant | Phase 3 | Recruiting | Janssen Research & Development, LLC | 348 | 2026-07-23 | 2026-11-03 |
| A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder Esketamine, Midazolam, Oral Placebo - Depressive Disorder, Major | Phase 3 | Recruiting | Janssen Research & Development, LLC | 258 | 2026-01-08 | 2026-11-03 |
| PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study Racemic ketamine, Spravato (Esketamine) - Depression | Phase 3 | Recruiting | Yale University | 400 | 2025-01-27 | 2026-09-08 |
| Fentanyl OR Esketamine for Traumatic PAIN (FORE-PAIN) Trial Fentanyl Citrate, Esketamine - Acute Pain Due to Trauma, Analgesia | Phase 3 | Terminated | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 235 | 2024-01-11 | 2026-09-15 |
| Esketamine Combined With Pregabalin on CPSP in Spinal Patients. S-ketamine and pregabalin, Normal saline and placebo capsule - Esketamine, Pregabaline | Phase 2 / Phase 3 | Unknown | Beijing Tiantan Hospital | 150 | 2023-11-10 | 2023-11-07 |
| The Efficacy and Safety of Esketamine in Elective Laparoscopic Surgery BT-KTM-I, Ketanest®S - Laparoscopy, Anesthesia, Intravenous | Phase 3 | Completed | Chengdu Brilliant Pharmaceutical Co., Ltd. | 358 | 2023-09-20 | 2024-07-29 |
| Adjunctive Esketamine for Analgesia in Mechanically Ventilated Septic Shock Patients Esketamine, Saline, Remifentanil + propofol - Septic Shock, Mechanical Ventilation Complication | Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 124 | 2023-05-31 | 2023-11-22 |
| The Effect of Esketamine Combined With Pregabalin on Chronic Postsurgical Pain in Patients After Craniotomy. S-ketamine and pregabalin, Normal saline and placebo capsule - Chronic Postsurgical Pain | Phase 2 / Phase 3 | Completed | Beijing Tiantan Hospital | 246 | 2021-12-20 | 2024-08-01 |
| Esketamine Combined With Pregabalin on Acute Postoperative Pain in Patients Undergoing Resection of Spinal Neoplasms. S-ketamine and pregabalin, Normal saline and placebo capsule - Esketamine, Pregabalin | Phase 2 / Phase 3 | Completed | Beijing Tiantan Hospital | 90 | 2021-12-01 | 2023-07-06 |
| Esketamine and Perioperative Depressive Symptoms Esketamine, Normal saline - Depressive Symptoms, Esketamine | Phase 2 / Phase 3 | Completed | Beijing Tiantan Hospital | 435 | 2021-02-19 | 2025-08-01 |
| An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives Esketamine - Depression | Phase 3 | Completed | Janssen-Cilag, S.A. | 41 | 2020-09-08 | 2023-09-14 |
| A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg - Depressive Disorder, Major | Phase 3 | Completed | Janssen-Cilag International NV | 676 | 2020-08-21 | 2025-04-29 |
| A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg - Depressive Disorder, Treatment-Resistant | Phase 3 | Withdrawn | Janssen-Cilag International NV | 2019-12-01 | 2025-04-27 | |
| A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression Esketamine 56 mg, Esketamine 84 mg, Placebo - Depressive Disorder, Treatment-Resistant | Phase 3 | Completed | Janssen Research & Development, LLC | 252 | 2018-05-25 | 2025-04-29 |
| 54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide Esketamine, Placebo, Standard of Care - Depressive Disorder, Major | Phase 3 | Completed | Janssen Research & Development, LLC | 230 | 2017-06-15 | 2025-04-29 |
| 54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide Esketamine, Placebo, Standard of Care - Depressive Disorder, Major | Phase 3 | Completed | Janssen Research & Development, LLC | 226 | 2017-06-09 | 2025-04-29 |
| A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression Esketamine, Placebo, Duloxetine (Oral Antidepressant) - Depressive Disorder, Treatment-Resistant | Phase 3 | Completed | Janssen Research & Development, LLC | 719 | 2015-10-01 | 2025-04-29 |
| A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression Esketamine (Intranasal Spray), Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant) - Treatment-resistant Depression | Phase 3 | Completed | Janssen Research & Development, LLC | 802 | 2015-09-30 | 2025-04-29 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression Esketamine, Placebo, Duloxetine (Oral Antidepressant) - Depressive Disorder, Treatment-Resistant | Phase 3 | Completed | Janssen Research & Development, LLC | 139 | 2015-08-20 | 2025-04-29 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression Esketamine, Placebo, Duloxetine (Oral Antidepressant) - Treatment-resistant Depression | Phase 3 | Completed | Janssen Research & Development, LLC | 346 | 2015-08-10 | 2025-04-29 |
Showing 20 of 23. Sign in to see all of them.
Depressive Disorder, Treatment-Resistant (8) · Depressive Disorder, Major (4) · Agnosia (3) · Depression (3) · Pain, Postoperative (3) · Drug-Related Side Effects and Adverse Reactions (1) · Pain (1) · Shock, Septic (1) · Spinal Cord Neoplasms (1) · Spinal Stenosis (1)
Janssen Research & Development, LLC (10) · Beijing Tiantan Hospital (4) · Janssen-Cilag International NV (2) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Chengdu Brilliant Pharmaceutical Co., Ltd. (1) · Janssen-Cilag, S.A. (1) · Medical University of Graz (1) · Nanfang Hospital, Southern Medical University (1) · University Hospital, Basel, Switzerland (1) · Yale University (1)
United States (11) · China (8) · Brazil (7) · Spain (7) · Belgium (6) · Poland (6) · France (5) · Germany (5) · Hungary (5) · Taiwan (5) · Austria (4) · Bulgaria (4) · Czechia (4) · Mexico (4) · South Africa (4)
Ruquan Han, M.D., Ph D. (3) · Markus W Hollmann, Prof. dr. dr. (1) · Mischa Wejbora, MD (1) · Ruquan Han, M.D., Ph D (1) · Samuel Wilkinson, MD (1) · Wen Ouyang, MD (1) · Wilhelm Ruppen, MD (1)
PMID 32860422, PMID 34235612, PMID 34510411, PMID 33128208, PMID 35022754, PMID 38557430, PMID 32367114, PMID 34288609, PMID 34973081, PMID 35816217, PMID 35904046, PMID 36149841, PMID 36273682, PMID 37019044, PMID 37439961, PMID 37568081, PMID 39428602, PMID 31109201, PMID 31166571, PMID 31290965, PMID 32270176, PMID 32316080, PMID 32412700, PMID 32861217, PMID 34293233, PMID 34412104, PMID 34750057, PMID 35441931, PMID 35473735, PMID 36525338, PMID 36841794, PMID 37158911, PMID 37558912, PMID 37792613, PMID 38025416, PMID 38025433, PMID 38169502, PMID 38169503, PMID 38501980, PMID 38954874, PMID 39435126, PMID 40420189, PMID 41245530, PMID 41674286, PMID 42119799, PMID 42298878
2014 (5), 2016 (2), 2018 (1), 2019 (1)